Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
QuintilesIMS
UBS
Healthtrust
Argus Health
US Army
Merck
McKinsey
Teva

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,560,122

« Back to Dashboard

Summary for Patent: 7,560,122
Title:Pharmaceutical dosage form bearing pregnancy-friendly indicia
Abstract: A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of erroneous dispensing of or erroneous ingestion of pharmaceutical dosage forms not intended for pregnant women. Also disclosed is a method for achieving improved patient compliance resulting in improved product effectiveness. Also disclosed is a method for diminishing the incidence of erroneous dispensing of or erroneous ingestion of dosage forms not intended for pregnant women. Said methods comprising providing a pharmaceutical dosage form, intended for use by pregnant women, bearing pregnancy-friendly indicia apt to graphically distinguish dosage forms intended to be used during pregnancy from others.
Inventor(s): Gervais; Eric (Laval, CA), Atanackovic; Gordana (Dollard-des-Ormeaux, CA), Hebert; Raymond (Ile Bizard, CA)
Assignee: Duchesnay Inc. (Laval, Quebec, CA)
Application Number:10/611,803
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 7,560,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Duchesnay DICLEGIS doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 021876-001 Apr 8, 2013 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,560,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2392486Jul 05, 2002

International Patents Family Members for US Patent 7,560,122

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200400835 ➤ Sign Up
Netherlands 1023797 ➤ Sign Up
Monaco 200066 ➤ Sign Up
Italy UD20030145 ➤ Sign Up
Ireland 20030484 ➤ Sign Up
Greece 1004641 ➤ Sign Up
Greece 20030100286 ➤ Sign Up
France 2841783 ➤ Sign Up
Canada 2392486 ➤ Sign Up
Belgium 1016043 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Merck
Cipla
Moodys
Colorcon
Express Scripts
US Department of Justice
Teva
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot